AMGN - Amgen Inc.
| Previous close | 222.79 |
| Open | 219.88 |
| Bid | 215.39 x 1100 |
| Ask | 221.00 x 800 |
| Day's range | 215.76 - 223.99 |
| 52-week range | 166.30 - 244.99 |
| Volume | 2,981,201 |
| Avg. volume | 2,211,411 |
| Market cap | 128.507B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | 16.92 |
| EPS (TTM) | 12.88 |
| Earnings date | 27 Apr 2020 - 03 May 2020 |
| Forward dividend & yield | 6.40 (2.87%) |
| Ex-dividend date | 12 Feb 2020 |
| 1y target est | 246.05 |
- Investing.com
Amgen Stock Falls 3%
Investing.com - Amgen (NASDAQ:AMGN) Stock fell by 3.01% to trade at $216.06 by 13:01 (18:01 GMT) on Monday on the NASDAQ exchange.
- Zacks
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
- Zacks
J&J Files Application for Darzalex Label Expansion With FDA
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
- Simply Wall St.
If You Had Bought Amgen (NASDAQ:AMGN) Shares Five Years Ago You'd Have Made 47%
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
- Zacks
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
- Zacks
Top Stock Research Reports for Alphabet, Roche & Amgen
Top Stock Research Reports for Alphabet, Roche & Amgen
- Zacks
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
- Zacks
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
- Zacks
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
- Zacks
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
- Investing.com
Amgen Stock Rises 6%
Investing.com - Amgen (NASDAQ:AMGN) Stock rose by 5.52% to trade at $234.04 by 14:02 (19:02 GMT) on Wednesday on the NASDAQ exchange.
- Zacks
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
- Zacks
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
- Zacks
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
- Zacks
Amazon Beats Big on Q4 Bottom Line; Plus V, AMGN
Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.
- Zacks
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
Amgen (AMGN) delivered earnings and revenue surprises of 5.81% and 3.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Q4 GDP 2.1%, In-Line with Q3; Plus Q4 Earnings from VZ, KO & More
Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.
- Investing.com
Amgen Earnings, Revenue Beat in Q4
Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
- Zacks
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
- Zacks
Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs
Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
- Zacks
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
